Patent · US Expired

Tetrahydroindolone and purine derivatives linked to arylpiperazines

US6770638B2 · kind B2 · utility

6Cited by
2References
12Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJul 30, 2002
Grant dateAug 3, 2004
Priority date
Expiry dateJul 30, 2022

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07D417/12
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Pharmaceutical composite compositions comprising tetrahydroindolones linked to arylpiperazines and derivatives thereof are disclosed. Specifically, composite compositions useful in treating anti-psychotic disorders are disclosed. The composite compositions disclosed herein can effectively ameliorate symptoms and treat psychotic disorders without causing a decrease in cognitive function. Generally, the composite compounds consist of two moieties, moiety A and B in which a tetrahydroindolone comprises a moiety A linked through a linker L to a moiety B, where B is an arylpiperazinyl moiety. The composite compound provides anti-psychotic actively by interaction with GABA, seratoninne and dopamine receptors. The composite molecules with the combined activities will provide treat psychiatric and neurological diseases without cognitive impairment.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.